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Sunmnary Fifty-two patients with epithelial ovarian cancer were treated with yttrium-90-labelled mono-
clonal antibody HMFG1 administered intraperitoneally following conventional surgery and chemotherapy as
part of an extended phase I-II trial.
The treatment was well tolerated and the only significant toxicity observed was reversible myelosuppression
as previously described. Following conventional surgery and chemotherapy, 21 out of the 52 patients had no
evidence of residual disease and were regarded as receiving treatment in an adjuvant setting. To date, two of
these patients have died of their disease (follow-up 3-62 months, median follow-up 35 months).
This extended phase I-II study suggests that patients with advanced ovarian cancer who achieve a complete
remission following conventional therapy may benefit from further treatment with intraperitoneal radioactive
monoclonal antibody.
Cancer of the ovary ranks sixth as a fatal form of cancer in
women (Young et al., 1982). Its incidence is approximately
20 per 100,000 with 4,500 new cases and 3,700 deaths per
annum in the United Kingdom (Department of Health 1987).
At diagnosis most patients have tumour outside the pelvis
and this probably accounts for the poor prognosis (FIGO
news report 1971). Advances in cytoreductive surgery and
postoperative chemotherapy in the last decade have produced
response rates of 65-80% but only a small improvement in
overall survival (Neijt et al., 1984). Unfortunately, most
patients relapse and die of their disease indicating that
benefits from surgery and chemotherapy, whether these may
be new drugs or new combination of old drugs have reached
a plateau (Marsoni et al., 1990).
More than 90% of epithelial ovarian tumours express high
levels of many antigens (Bast et al., 1991), including one in
particular, known as polymorphic epithelial mucin (PEM)
(Gendler et al., 1987). PEM can be described as a 'tumour
associated antigen' because although expressed extensively by
many epithelial cancers it can also be found at low levels on
many normal tissues (Arklie et al., 1981). Several monoclonal
antibodies to this antigen and its various epitopes have been
made and used for in vitro and in vivo diagnosis of many
cancers including ovarian cancer (Epenetos et al., 1982;
Pateisky et al., 1985; Colcher et al., 1983). Since 1983, we
have been investigating the possibility of tumour targeting
and therapy by the intraperitoneal administration of
radiolabelled monoclonal antibodies in patients with ovarian
cancer (Epenetos et al., 1984).
We have previously described extensively the pharmaco-
kinetics, biodistribution and toxicity of iodine-131 and
yttrium-90-labelled monoclonal antibodies for the treatment
of ovarian cancer (Epenetos et al., 1987; Stewart et al., 1989,
1990; Maraveyas et al., 1993). In this report we present the
first comprehensive survival data of patients treated in this
way from October 1987 to December 1992. Based on our
results we propose that this novel modality should now be
considered further as a form of adjuvant in patients with
cancer of the ovary.
Patients, materials and methods
Patients
Fifty-two patients with known epithelial cancer received in-
traperitoneal radioimmunotherapy with yttrium-90-labelled
monoclonal antibody HMFG1. Patients' ages ranged from
29-76 years. All had performance status above WHO Grade
2. All patients had previously undergone cytoreductive
surgery, and all but one were subsequently treated with
cisplatin or carboplatin based chemotherapy. One patient
(Stage Ic) did not receive chemotherapy. Table I shows the
stage and disease status at presentation of all treated patients
and Table lb shows the histology and stage of patients
treated as adjuvant, as assessed at second look laparoscopy.
It can be seen that there are 22 patients who had no evidence
of disease at the time of laparoscopy. One (Stage la) was
disease free following chemotherapy for relapse and the
remaining 21 were regarded as receiving treatment in an
adjuvant setting.
Monoclonal antibody
The monoclonal antibody used in this study was Human
Milk Fat Globule 1 (HMFGI) (ICRF, London and Unipath
(UK) Ltd, Bedford). HMFG1 is a mouse IgGI monoclonal
antibody that binds to the PEM molecule found on more
than 90% of epithelial ovarian carcinomas (Arklie et al.,
1981). Patients received 25 mg of antibody.
Antibody labelling
Yttrium-90 (AERE Harwell, UK) was chelated to the anti-
body-DTPA, CITC-DTPA or -DOTA conjugate as previ-
ously described (Stewart et al., 1990; Meares et al., 1990).
Free radioisotope was removed by sephadex G50 gel filtra-
tion using phosphate buffered saline as elution buffer.
Specific activity of radiolabelled antibody was <5 Ci mg '1.
The final dose of administered antibody was made up to
25 mg of total IgG by adding unlabelled HMFG1 IgG to the
radiolabelled fraction. Antibody immunoreactivity was tested
in an enzyme-linked immunosorbant assay (ELISA method)
before and after radiolabelling and was compared with
underivatised antibody using micro titre plates coated with
purified antigen. No obvious reduction in immunoreactivity
was seen. The administered dose of radioactivity was
measured in a SIEL isotope calibration chamber that had
been calibrated with an yttrium-90 source (Stewart et al.,
1990).
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Table Ia Patient's number, FIGO stage and extent of disease at
antibody treatment
Patient FIGOstage Diseasestage at
no. atpresentation antibody therapy
1 1a Noevidence ofdiseasefollowing relapse
2 la Bulkya disease + ascites
3 1c Noevidenceofdisease
4 Ic Noevidenceofdisease
5 1c Positiveperitonealwashings
6 1c Noevidenceofdisease
7 2a Unassessable adhesions
8 2b Noevidenceofdisease
9 2b Noevidenceofdisease
10 2c No evidenceofdisease
11 2c Noevidenceofdisease
12 III Noevidenceofdisease
13 III Noevidenceofdisease
14 III Unassessable adhesions
15 III Bulkydisease
16 III Bulkydisease
17 III Bulkydisease
18 III Bulkydisease
19 III Minimalbdisease
20 III Minimal disease
21 III Bulky disease
22 III Bulkydisease
23 III Bulky disease
24 III Noevidence ofdisease
25 III Bulky disease
26 III Minimal disease
27 III Unassessable adhesions
28 III Bulkydisease
29 III Noevidenceofdisease
30 IV Noevidence ofdisease
31 IV Noevidence ofdisease
32 IV Extraperitoneal disease
33 Ic Bulkydisease
34 III Noevidenceofdisease
35 III Bulky disease
36 III Minimal disease
37 III Bulkydisease
38 III Minimal disease
39 IV Bulkydisease
40 III Bulkydisease
41 III Minimal disease
42 Ila Noevidence ofdisease
43 Ic Noevidenceofdisease
44 IIc Noevidence ofdisease
45 III Noevidence ofdisease
46 III Unassessable
47 Ic No evidence ofdisease
48 III Unassessable
49 IV Bulky disease
50 III Noevidence ofdisease
51 III No evidence ofdisease
52 III Noevidence ofdisease
aBulkydisease = >2cm. bMinimal disease = <2 cm.
Treatment
A peritoneal dialysis catheter was inserted into the peritoneal
cavity during laparoscopy. Open laparoscopy also allowed
visual assessment of disease volume, including peritoneal
lavage with normal saline for cytological assessment. Minor
adhesions, particularly around the liver, were noted in some
patients. A good view was obtained in all but five patients,
however, all patients were treated. Following the laparo-
scopy, yttrium-90-labelled antibody (dose range 5.00-
30.000 mCi) was infused into the peritoneal cavity with 1.5
litres normal saline or Hartman's solution and the peritoneal
dialysis catheter was removed. The patient position was
altered every 20 min for the first 2 h to encourage an even
distribution of antibody. Patients were nursed in a radiation
controlled area for 5 days, during which time blood and
urine samples were counted in order to monitor the blood
levels of radioactivity and urinary excretion of the
radioisotope, respectively.
Table lb FIGO stage and histology of patients treated in an
adjuvant setting
No.
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
Stage
atpresentation
Ic
Ic
Ic
IIb
IlIb
IIc
IIc
III
III
III
III
IV
IV
III
Ila
Ic
Ilc
III
Ic
III
III
Histology
Endometrioid
Endometrioid
Serous
Undifferentiated
Serous
Undifferentiated
Endometrioid
Endometrioid
Endometrioid
Undifferentiated
Endometrioid
Undifferentiated
Serous
Serouscystadenocarcinoma
Clearcell
Serouscystadenocarcinoma
Well differentiated
Serous
Undifferentiated
Serous
Endometrioid
Pharmacokinetics
Pharmacokinetics, toxicity and dosimetry have been previ-
ously reported (Epenetos et al., 1987; Stewart et al., 1989,
1990; Maraveyas et al., 1993). Approximately 30% of the
intraperitoneally injected immunoconjugate was absorbed
into the systemic circulation by 48 h after administration
(Stewart et al., 1989, 1990; Maraveyas et al., 1993).
Results
Toxicity
The treatment was well tolerated by all patients. Reversible
myelosuppression was observed at high doses (> 15 mCi of
HMFG1-DTPA-90Y). This toxicity was reduced considerably
by the subsequent use of more stable chelating agents known
as DOTA and CITC-DTPA (Moi et al., 1990). No significant
myelotoxicity was observed even at higher doses of up to
20mCi of HMFGI-DOTA-9Y (Kosmas et al., 1992) and
34 mCi of HMFG1-CITC-DTPA-9Y. A correlation between
body surface and CITC-DTPA-9Y dose was found
(Maraveyas et al., 1993). DOTA is potentially immunogenic
in patients (Kosmas et al., 1992) as three out of six patients
treated with HMG1-DOTA-9Y conjugate developed serum
sickness reactions manifested as superficial and self limiting
skin rashes 10-12 days after treatment. It was also found
that treated patients developed anti-DOTA (Kosmas et al.,
1990) and anti-CITC-DTPA antibodies. All patients
developed human antimouse antibodies as previously
reported (Epenetos et al., 1987; Stewart et al., 1989). The
difference in toxicity and immunogenicity between DTPA
and DOTA linkage between antibody and radionuclide as
well as the HAMA levels are reported elsewhere (Kosmas et
al., 1992; Maraveyas et al., 1993).
Survival
Figure 1 shows the survival data of the subgroup of 15
patients treated regarded as receiving adjuvant treatment and
compares it with a similar group (70 patients) from the same
centre (North Thames Ovarian Group). This group com-
prises of patients who presented with Stage 1lb disease or
worse and had no evidence of residual disease at laparoscopy
following conventional treatment with surgery and
chemotherapy. These data show a remarkable difference in
survival between the group treated as adjuvant with antibody
and the historical control from the North Thames Ovarian
Group (Lambert et al., 1993). However, this is not the resultADJUVANT THERAPY OF OVARIAN CANCER 405
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Figure 1 Actuarial survival of patients treated in an adjuvant setting with monoclonal antibodies. In this Figure a comparison is
made of the 15 patients (Stage Ilb or greater) adjuvant group treated with antibody and a group of 70 patients from the North
Thames ovarian Group who presented with at least Stage Ilb disease and who had no evidence of disease at second look
laparoscopy. These patients were further randomised to receive further chemotherapy or whole abdominal radiotherapy (Lambert
et al., 1993). A further six patients who had stage Ic-IIa disease and were treated similarly with radiolabelled monoclonal
antibodies are not shown on this graph. One patient of this group has died.
of a randomised trial, and the patient numbers are small.
Survival after antibody therapy ofpatients with bulky disease
treated with radiolabelled antibody is: median survival of 11
months (range 2-31 months), with four patients still alive.
Discussion
The application of radiolabelled antibodies as specific
cytotoxic drugs against cancer has many attractions including
selectivity against tumour cells, irradiation of adjacent
tumour cells, lack of major side effects and simplicity of
radiolabelling and administration. Although tested exten-
sively over the last decade, radiolabelled and other
immunoconjugates have had only limited success as anti-
cancer agents.
For the first time, this study demonstrates that radio-
labelled antibodies used in an adjuvant setting may reduce
the rate of recurrence from ovarian cancer and improve the
long term survival. Although survival data from this study
appear superior to previously reported studies (Neijt et al.,
1984; Marsoni et al., 1990), the patient numbers are small
and need to be substantiated by larger phase III randomised
studies. Furthermore, because this was a phase I-II study,
our cases included a mixture of stages from Ic-IV.
The mechanisms for the action ofantibody therapy are not
clear from this trial. The calculated doses of radiation
delivered by the radioactive antibody are thought to be
insufficient for a cytotoxic effect based on calculations using
conventional dosimetry tables (Snyder et al., 1978) although
more recent studies suggest that higher doses can be delivered
(Larson et al., 1991). Unfortunately, there are no comprehen-
sive data on the therapeutic efficacy of radioactive yttrium
colloid alone given intraperitoneally after chemotherapy. An
alternative possibility is that HMFG1 murine monoclonal
antibody when administered intraperitoneally into humans,
can cause a cascade of immunological reactions leading to
humoral (Courtenay-Luck et al., 1988; Herlyn et al., 1991)
and cellular (Kosmas et al., 1991) activation of the immune
system with resultant antitumour effects. If this is the cause
of the observed prolongation of survival in patients with
ovarian cancer in this study, then, ironically, the use of
murine monoclonal antibodies may be more effective than
the recently described chimeric (LoBuglio et al., 1989),
humanised (Reichmann et al., 1988) or completely human
(Borrebaeck et al., 1988) monoclonal antibodies.
In summary, this study provides encouragement to the
concept of adjuvant therapy with monoclonal antibodies in
patients with epithelial ovarian cancer who have no evidence
of residual disease after initial surgery and chemotherapy.
We are grateful to the following: D. Allen, R. Biruls, C. Coulter, R.
Chandler and J. Taylor-Papadimitriou.
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